Rhys Whomsley

Pharmacokinetics and metabolism of 14 C-levetiracetam, a new antiepileptic agent, in healthy volunteers

M. Strolin Benedetti, Rhys Whomsley, Jean‐Marie Nicolas et al. · European Journal of Clinical Pharmacology · 2003 · 105 citations

Medicine, Pharmacokinetics, Pharmacology +11

Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA)

Naomi L. Kruhlak, Marianne Schmidt, Roland Froetschl et al. · Regulatory Toxicology and Pharmacology · 2024 · 73 citations · Full text

Pharmacy, Pharmacology, Toxicology +13

Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog

M. Strolin Benedetti, René Coupez, Rhys Whomsley et al. · Xenobiotica · 2004 · 63 citations

Medicine, Pharmacokinetics, Pharmacology +13

Substituted 1-[(benzofuran-2-YL)-phenylmethyl]-imidazoles as potent inhibitors of aromatase in vitro and in female rats in vivo

Rhys Whomsley, E Munoz Fernandez, Paul J. Nicholls et al. · The Journal of Steroid Biochemistry and Molecular Biology · 1993 · 45 citations

Medicine, Medicinal Chemistry, Pharmacology +12

The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation

M L Slevin, Simon P. Joel, Rhys Whomsley et al. · Cancer Chemotherapy and Pharmacology · 1989 · 39 citations

Pharmacy, Pharmacokinetics, Pharmacology +7